Progress, Potential, and Possibilities Podcast / Show · 2026-07-07 · 48 min
Send us Fan Mail What if radiation could become one of the most precise medicines ever invented? Long before radiopharmaceuticals became one of the hottest areas in biotech, today's guest was helping pioneer targeted radiation therapies that seek out cancer cells while minimizing damage to healthy tissue. Today, the field is attracting billions in investment and reshaping oncology. Our guest today is one of the true pioneers of modern targeted radiopharmaceutical therapy. Dr. Ebrahim Delpassand, MD is the Founder, Chairman and CEO of RadioMedix ( ), a clinical-stage biotechnology company developing next-generation targeted radioactive diagnostics and therapeutics for cancer. Long before radiopharmaceuticals became one of the most exciting areas in precision oncology, Dr. Delpassand was introducing these therapies to patients who had exhausted every other option. As former Deputy Chairman and Chief of Clinical Nuclear Medicine at MD Anderson Cancer Center, Dr.
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
How Healthcare Moves from Reactive Care to Preventive with Ray PawlickiBiology Matters · on Precision medicine83 / 100
US Pharma Deals Midyear Outlook 2026: Why Dealmakers Are Leaning Into GrowthPwC's Next in Health · on Oncology76 / 100
Healthcare AI Is Failing And the Fix Isn't More DataSaaS That App · on Precision medicine73 / 100
Longevity Is the New Wealth: Inside Fountain Life's Vision with Dr. William KappEntrepreneurs on Fire · on Precision medicine60 / 100
Solving Patient Matching in Rare Disease TrialsP4A Let's Talk Rare: The Life Science Podcast · on Precision medicine56 / 100
This Just In Radio: CancerX 2026 with Joanna Weiss and Matthew BednarThis Just In Radio Show · on Precision medicine53 / 100Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100The Blood Test That Could Change Cancer Treatment Forever | Eric Matthews - General Manager, Biopharma, Natera65 / 100How Female Biology Shapes Skin Disease Across a Lifetime | Dr. Doral Fredericks, PharmD, MBA - Vice President and Head of Global Medical Affairs and Outcomes Research, Organon56 / 10055 Years Without a Diagnosis | Can AI Solve The Undiagnosed Condition Blind Spot? | Haresh Patel - Founder and CEO, Sanare Health AI70 / 100How Regenerative Medicine Is Reinventing Breast Reconstruction | Dr. Claudia Chavez-Munoz, MD, PhD - Chief Scientific Officer and Co-Founder - Conexeu Sciences